Updates are available Correction dated 2023-08-14
Click to view Correction: https://0-doi-org.brum.beds.ac.uk/10.1186/s40246-023-00518-z
-
Authors
Lee, Ning-Yuan
Hum, Melissa
Zihara, Sabna
Wang, Lanying
Myint, Matthew K.
Lim, Darren Wan-Teck
Toh, Chee-Keong
Skanderup, Anders
Samol, Jens
Tan, Min-Han
Ang, Peter
Lee, Soo-Chin
Tan, Eng-Huat
Lai, Gillianne G. Y.
Tan, Daniel S. W.
Yap, Yoon-Sim
Lee, Ann S. G.
- License Information
-
More Information
Article History
Received: 10 May 2023
Accepted: 10 July 2023
First Online: 17 July 2023
Change Date: 14 August 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://0-doi-org.brum.beds.ac.uk/10.1186/s40246-023-00518-z
Declarations
:
: Written informed consent was obtained from all patients and the study was approved by the SingHealth Centralised Institutional Review Board (CIRB Ref: 2018/2147 and 2018/2963).
: Not applicable.
: P.A. reports receiving travel support and/or honoraria from AstraZeneca, DKSH, Eisai, Bristol Myers Squibb, Lilly, Novartis, Pfizer, Roche, and MSD, all of which are outside the submitted work. M.-H.T. reports being a director, shareholder, and Chief Executive Officer of Lucence, outside of the submitted work. S.-C.L. reports grant support/research collaborations with Pfizer, Eisai, Taiho, ACT Genomics, Bayer, and MSD; advisory board/speaker invitations from Pfizer, Novartis, Astra Zeneca, ACT Genomics, Eli Lilly, MSD, Roche, Eisai and Daiichi-Sankyo; conference support from Amgen, Pfizer and Roche, all of which are outside the submitted work. No other disclosures were reported.
